Shares of Ultragenyx Pharmaceutical cratered 45% overnight after its most-watched experimental therapy — a gene-silencing drug for Angelman syndrome, a rare disorder that causes severe intellectual disabilities in children — showed zero benefit over a sham treatment in a definitive late-stage trial. The Phase 3 failure erased roughly $1.14 billion from the company's market value , dropping the stock to $14.45 and raising hard questions about whether a once-promising rare-disease pipeline can keep this company alive.
• Early Excitement Didn't Survive Rigorous Testing. The drug had shown powerful results in early trials, raising the hopes of families affected by the devastating condition. But in the 129-patient Phase 3 study, there were no differences between the treated and control groups on cognitive scores or across all five components of a broader clinical measure. This is the second Phase 3 collapse in under a year for Ultragenyx, which suffered a similar miss in its bone-disease program in late 2025. Evercore ISI called the result "a clean fail" — leaving essentially no path to salvage the data for approval.
• The Company Is Now Cutting Costs to Survive. Ultragenyx said it will evaluate whether to continue the Angelman program and plans to "define and implement significant expense reductions" while supporting its existing commercial business. That commercial base is real — the company reaffirmed 2026 revenue guidance of $730–$760 million — but it lost $92 million in Q2 alone, with operating cash burn reaching $294 million in the first half of 2026. With cash and marketable securities at $436 million , the runway is finite without new revenue engines.
• Analyst Price Targets Are Plunging Toward the Stock Price. Before the failure, targets ranged from $48 to $96. Evercore ISI immediately downgraded to neutral, slashing its target to $16 — implying a market cap of just $1.7 billion. Angelman was widely viewed as the company's single largest long-term revenue opportunity; stripping it out forces investors to value Ultragenyx on its existing drugs and remaining gene-therapy bets alone.
• One Lifeline Remains This Month. The FDA has a September 19 decision date on UX111, a gene therapy for Sanfilippo syndrome. An approval could provide a badly needed catalyst, but it arrives with its own baggage — a prior rejection tied to manufacturing problems . For shareholders, the next 16 days will determine whether Ultragenyx is a turnaround story or simply a shrinking one.